Login to Your Account


Cangene purchase propels Emergent Biosolution’s biodefense goals

By Marie Powers
Staff Writer

Friday, December 13, 2013

Emergent Biosolutions Inc. took another step in its quest to expand its pipeline and ramp up commercial revenues by sealing a deal to acquire Canada’s Cangene Corp. for $222 million, or $3.24 per share on a fully diluted basis. The boards of directors of both companies approved the transaction, which gives Emergent three specialty products included in the U.S. Strategic National Stockpile and four commercial specialty therapies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription